WallStreetZenWallStreetZen

NASDAQ: BBOT
Bridgebio Oncology Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their BBOT stock forecasts and price targets.

Forecast return on equity

Is BBOT forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is BBOT forecast to generate an efficient return on assets?

Company
-117.55%
Industry
45.93%
BBOT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BBOT earnings per share forecast

What is BBOT's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$2.18
Avg 2 year Forecast
-$2.33
Avg 3 year Forecast
-$2.98

BBOT revenue forecast

What is BBOT's revenue in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
$75.0M
Avg 2 year Forecast
$279.0M

BBOT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BBOT$8.94N/AN/A
SEPN$12.10$23.00+90.08%Buy
ORKA$14.80$43.33+192.79%Buy
GOSS$2.47$8.50+244.13%Strong Buy
SVRA$3.28$5.00+52.44%Buy
View Top Biotech Stocks

Bridgebio Oncology Therapeutics Stock Forecast FAQ

What is BBOT's earnings growth forecast for 2025-2027?

(NASDAQ: BBOT) Bridgebio Oncology Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.22%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 14.8%.

Bridgebio Oncology Therapeutics's earnings in 2025 is -$106,510,370.On average, 3 Wall Street analysts forecast BBOT's earnings for 2025 to be -$132,996,370, with the lowest BBOT earnings forecast at -$210,795,000, and the highest BBOT earnings forecast at -$84,318,000. On average, 3 Wall Street analysts forecast BBOT's earnings for 2026 to be -$142,161,370, with the lowest BBOT earnings forecast at -$215,072,000, and the highest BBOT earnings forecast at -$83,096,000.

In 2027, BBOT is forecast to generate -$181,772,500 in earnings, with the lowest earnings forecast at -$216,294,000 and the highest earnings forecast at -$147,251,000.

If you're new to stock investing, here's how to buy Bridgebio Oncology Therapeutics stock.

What is BBOT's revenue growth forecast for 2030-2031?

(NASDAQ: BBOT) Bridgebio Oncology Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.25%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.49%.

Bridgebio Oncology Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast BBOT's revenue for 2030 to be $4,582,500,000, with the lowest BBOT revenue forecast at $4,582,500,000, and the highest BBOT revenue forecast at $4,582,500,000.

In 2031, BBOT is forecast to generate $17,046,900,000 in revenue, with the lowest revenue forecast at $17,046,900,000 and the highest revenue forecast at $17,046,900,000.

What is BBOT's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: BBOT) forecast ROA is -117.55%, which is lower than the forecast US Biotechnology industry average of 45.93%.

What is BBOT's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: BBOT) Bridgebio Oncology Therapeutics's current Earnings Per Share (EPS) is -$562.36. On average, analysts forecast that BBOT's EPS will be -$2.18 for 2025, with the lowest EPS forecast at -$3.45, and the highest EPS forecast at -$1.38. On average, analysts forecast that BBOT's EPS will be -$2.33 for 2026, with the lowest EPS forecast at -$3.52, and the highest EPS forecast at -$1.36. In 2027, BBOT's EPS is forecast to hit -$2.98 (min: -$3.54, max: -$2.41).

What is BBOT's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: BBOT) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.